Leviogel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Leviogel

Quick Facts

Property Description
Active ingredient Diclofenac (as Diclofenac Sodium)
Form Topical Gel
Pharmacological class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use Relief of localized pain and swelling
Origin Synthetic (Phenylacetic acid derivative)

What is Leviogel and What Type of Medicine is it?

Leviogel is a medicinal product used for the localized relief of painful and inflammatory states within the body's soft tissues. It is fundamentally classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), a class globally recognized for its analgesic and anti-inflammatory properties. The active ingredient, Diclofenac, is a synthetic phenylacetic acid derivative designed exclusively for topical administration. This formulation distinguishes it from oral forms of NSAIDs, as the product is positioned for local action, resulting in generally lower systemic exposure compared to ingestible counterparts.

Diclofenac: Composition and Formulation as a Topical Gel

The sole active ingredient responsible for the therapeutic action in Leviogel is Diclofenac (typically present as Diclofenac Sodium), which is supplied in a topical gel dosage form. This single-ingredient product utilizes a specialized hydroalcoholic gel base, a vehicle chosen to facilitate the efficient percutaneous penetration of the Diclofenac through the skin. This formulation is clinically recognized for its ability to target soft tissue injuries. This means the drug is effective when applied to the skin to reach the source of the discomfort, offering focused relief. This gel formulation, intended for external use, allows the active substance to be released rapidly and delivered effectively to the underlying tissues.

General Purpose and Anti-Inflammatory Action

The general purpose of Leviogel is to offer relief from localized discomfort and swelling associated with phlogistic states in soft tissues, such as those that may occur in muscles or joints. As an NSAID, the Diclofenac in the gel is designed to provide a targeted anti-inflammatory and analgesic (pain-relieving) effect directly where applied. This local action helps mitigate the biological response to irritation, focusing the therapeutic benefit on the affected area without relying on extensive distribution throughout the body.

Regulatory References

  1. NIH on NSAIDs

What side effects are possible with Leviogel?

Possible Side Effects and Safety Information

The safety profile of Leviogel, which contains the NSAID Diclofenac for topical use, is officially documented primarily by regulatory agencies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). The known adverse events are generally localized to the application site.

Official Adverse Reactions by Frequency

The following side effects are classified according to standard regulatory frequency categories:

Classification Examples of Reactions
Common (1 to 10 in 100 users) Dermatitis (including contact dermatitis), pruritus (itching), erythema (redness), and localized rash.
Rare (1 to 10 in 10,000 users) Bullous dermatitis (skin inflammation with large blisters).
Very Rare (less than 1 in 10,000 users) Hypersensitivity reactions (such as angioedema), asthma (in susceptible individuals), and photosensitivity reactions (following UV exposure).

Serious Adverse Reactions and Safety Constraints

The product label documents the potential for serious, though very rare, systemic adverse reactions associated with systemic NSAID exposure, including Stevens-Johnson syndrome and toxic epidermal necrolysis. These risks are noted due to the possibility of absorption, though the risk is low for proper topical application.

Official Safety Restrictions:

  • Contraindications: The gel is contraindicated for individuals with known hypersensitivity to Diclofenac, aspirin, or any other NSAID. It must not be applied to non-intact skin (e.g., open wounds, infections, or eczema) or mucous membranes.
  • Pregnancy and Lactation: Use is contraindicated during the third trimester of pregnancy due to risk to the fetus. It should also not be applied to the breast area during lactation.

Exposure-Related Risk: The official documentation specifies that the potential for systemic side effects is related to the size of the application area and the duration of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory sources indicate that an overdose of Diclofenac Topical Gel is generally unlikely due to the low systemic absorption of the active ingredient during topical use. The primary overdose concern is the risk associated with accidental oral ingestion of the gel, which can lead to systemic adverse events mirroring an overdose of oral nonsteroidal anti-inflammatory drugs (NSAIDs).

Documented Overdose Presentations

System Affected Manifestations (If Ingested)
Gastrointestinal Epigastric pain, nausea, vomiting, abdominal cramps, and severe outcomes like bleeding, ulceration, or perforation.
Central Nervous System Headache, dizziness, drowsiness, confusion, and potential for seizures or coma in severe cases.
Systemic/Other Potential for renal or hepatic toxicity, as well as serious cardiovascular thrombotic events (myocardial infarction, stroke).

Mandated Emergency Actions

Immediate medical help is required for any signs of a life-threatening complication, including:

  • Signs of a heart attack or stroke (e.g., sudden weakness, chest pain, slurred speech) ([1.4], [1.2]).
  • Evidence of serious stomach bleeding (e.g., black or tarry stools, vomiting blood) ([1.4]).
  • Symptoms of a severe allergic reaction, such as anaphylactic reactions ([1.2]).
  • If the product is swallowed, contact a Poison Control Center or seek medical help right away ([1.4]).

If the recommended topical dose is significantly exceeded, the regulatory instruction is to remove the gel from the skin and wash it off with water ([1.7]). For accidental ingestion, management involves general therapeutic measures for NSAID poisoning, with consideration for gastric lavage and activated charcoal ([1.7]). The risk of serious adverse events is elevated for the elderly and those with existing renal or hepatic impairment ([1.4]).

Therapeutic Uses of Leviogel

What Leviogel Treats: Main Uses and Benefits

Leviogel is a topical medication used for the local management of pain and inflammation. Its primary purpose is to address painful and inflammatory conditions that are related to issues within the musculoskeletal system, including joints, muscles, tendons, and ligaments. These conditions may result from either a rheumatic origin or from physical trauma.

Specifically, the gel is authorized for use in the temporary relief of symptoms associated with:

  • Joint pain (e.g., from certain forms of arthritis).
  • Muscle aches.
  • Inflammation of soft tissues that can occur after injuries like sprains or strains.

The application of Leviogel may contribute to the alleviation of localized discomfort and can support the management of inflammation in the affected area. This topical approach allows for targeted relief.


Quick Facts

  • Therapeutic Domain: Local relief of pain and inflammation.
  • Primary Indications: Painful conditions of the joints, muscles, tendons, and ligaments.
  • Context of Use: Rheumatic states and physical trauma/injuries.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Leviogel (Diclofenac Topical Gel) is subject to official population eligibility rules defined by government regulatory agencies. These rules specify who can use the medicine and who must not, based primarily on pre-existing sensitivities and patient health status.

Classification Eligibility Rule (Official Basis)
Absolute Contraindications History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs (Nonsteroidal Anti-Inflammatory Drugs). bullet Known hypersensitivity to diclofenac or any of the product's components. bullet Use in women starting at 30 weeks gestation (third trimester of pregnancy). bullet Use in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Age-Based Restrictions Children and adolescents under 14 years of age are generally not recommended for use due to insufficient safety and efficacy data. bullet Older adults may use the medicine but require caution due to potential comorbidities.
Conditional/Restricted Use Severe Heart Failure or Advanced Renal Disease: Use must be avoided unless the therapeutic benefit is deemed to outweigh the risk of worsening the existing condition. bullet Pregnancy (1st/2nd Trimesters): Use is generally not recommended unless considered clearly necessary. bullet Application Site: Must not be applied to damaged skin, open wounds, eyes, or mucous membranes.

The regulatory profile clearly defines both who is officially excluded from use and the conditions under which the medicine requires special patient monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

The official regulatory profile for Diclofenac Topical Gel addresses potential systemic interactions associated with the Nonsteroidal Anti-inflammatory Drug (NSAID) class, despite the product's intended local action and low systemic absorption.

Medicinal product categories with documented interactions: Other oral NSAIDs, Analgesics, Medicines that Interfere with Hemostasis, Antihypertensives, Diuretics, Digoxin, and other Topical Products.

Interaction-Related Restrictions

Concomitant use with oral NSAIDs or analgesic doses of Aspirin is not generally recommended due to the potential for increased systemic adverse effects, including serious Gastrointestinal bleeding.

Classification Constraint / Requirement
Pharmacodynamic Risk Co-administration with Medicines that Interfere with Hemostasis (e.g., Warfarin) increases the risk of serious GI bleeding; the label mandates monitoring for bleeding.
Antihypertensive Agents Use with ACE Inhibitors, ARBs, or Beta-Blockers may diminish the antihypertensive effect; monitoring of blood pressure is required.
Exposure Alteration Co-administration with Digoxin can increase its serum concentration and half-life; monitoring of serum Digoxin levels is mandated.
Timing Restriction Application of other topical products on the same skin site as the gel should be avoided.

Population-Specific Notes

A heightened risk of renal function deterioration is noted for elderly, volume-depleted, or renally impaired patients when co-administered with ACE Inhibitors or ARBs; monitoring for signs of worsening renal function is mandated.

Mechanism of Action

Targeted Inhibition of Prostaglandin Synthesis

Leviogel's mechanism is centered on the non-competitive reversible inhibition of Cyclooxygenase (COX) enzymes, primarily focusing on the inducible COX-2 isoform. This action blocks the upstream molecular step in the eicosanoid pathway, halting the conversion of arachidonic acid into pro-inflammatory prostaglandins.


Modulation of Local Inflammatory and Nociceptive Signaling

By restricting the supply of prostaglandins, the drug exerts its primary physiological effect at the application site. The resulting molecular deficiency causes a reduction in prostaglandin-mediated capillary permeability and subsequent fluid extravasation into tissues. Simultaneously, the reduction in these mediators prevents the sensitization of peripheral nociceptors, consequently increasing the threshold for activation of these sensory nerve endings.


Mechanism Limitations: Physiological Constraint

The action of Diclofenac influences the physiological response to tissue irritation, indicating that the mechanism alters the local chemical mediator concentration. The mechanism does not address the underlying pathology or reverse existing structural tissue damage. Furthermore, the mechanistic effect is dependent on achieving a high local concentration of the active substance through percutaneous penetration.

Dosage and Administration Information

How Leviogel is Used: Official Administration Guidelines

Leviogel (Diclofenac Topical Gel) is intended solely for cutaneous use, meaning it is applied externally and directly to the skin. The administration pattern is standardized to ensure proper local delivery of the active substance.


Dosing and Measurement

The official regimen requires precise measurement of the gel, typically using the dosing card or applicator supplied with the product. The quantity applied is specific to the area being treated: for instance, a larger strip of gel (e.g., 4 grams) is often used for lower extremities, while smaller strips (e.g., 2 grams) are applied to upper extremities. The total daily quantity of the gel should not exceed the maximum regulatory dose of 32 grams across all treated sites.


Frequency and Procedural Rules

The labeled frequency involves scheduled applications, usually two to four times daily, which should be massaged gently into the entire affected area of intact, non-diseased skin. It is required to wash hands immediately after application, unless the hands themselves are the site of treatment. The use of airtight occlusive dressings is generally restricted.


Duration and Population Rules

The duration of use is typically limited and must be reviewed after a short course, such as 7 to 14 days. For older adults, the standard adult dosing regimen is often appropriate, but the gel is not generally recommended for use in children under the age of 14.

Recent Clinical Evidence

Leviogel: Recent Clinical Evidence

Research Evidence for Pain Associated with Osteoarthritis

Clinical trials that evaluated topical diclofenac focused on Osteoarthritis (OA), a condition marked by functional limitations and outcomes related to physical discomfort. The primary research consists of intermediate-term Randomized Controlled Trials (RCTs). These studies were designed to compare the active gel to an inactive vehicle (placebo) and primarily included adults diagnosed with symptomatic OA of the knee and hand. Research examined outcomes such as shifts in pain intensity and changes in daily functioning or activity level using validated scales. Findings describe patterns observed in these trials related to differences in patient-reported experience between the active and control groups over defined time intervals.

Research Evidence for Acute Soft Tissue Injuries

Leviogel was also studied for acute musculoskeletal conditions, including sprains, strains, and contusions. The evidence base consists of short-term Randomized Controlled Trials (RCTs), typically lasting 7 to 14 days. These studies monitored how symptoms evolved in the observed populations, and primary measurements examined the rate of change in pain intensity and the total time until symptoms returned to pre-study levels. Systematic reviews have pooled this short-term evidence, which helps contextualize reported patient experience in these acute research scenarios.

Research Limitations and Data Gaps

The evidence is limited regarding effects over extended periods; long-term outcomes extending beyond the intermediate follow-up are not fully established. Follow-up durations were constrained in many studies, and research is predominantly focused on the knee and hand, meaning data for certain large joints, such as the hip, remain insufficient. Furthermore, data for certain special populations, such as those with multiple comorbidities, are lacking, and the results apply only to the specific populations studied in the trials.

Key Studies & References

  1. Topical Diclofenac Therapy For Osteoarthritis: A Meta-analysis Of Randomized Controlled Trials

Frequently Asked Questions (FAQ)

Common questions about Leviogel (FAQ)


Q: Is Leviogel the same kind of medicine as other topical gels for similar conditions?

A: Official product information describes Leviogel as a topical gel containing the active ingredient diclofenac. This means it belongs to the Nonsteroidal Anti-Inflammatory Drug (NSAID) class of medicines. Its formulation is specifically designed for local action, allowing it to penetrate the skin and work directly at the site of discomfort, which distinguishes it from other types of pain relief products, such as oral NSAIDs.


Q: How quickly should someone expect to feel the effects of Leviogel?

A: Pharmacological data available on topical diclofenac suggests that the initial onset of action, where the active substance begins to work, has been reported to occur within 4 hours. However, for chronic conditions such as arthritis pain, official studies indicate that patients may need up to 7 days of continuous application to experience noticeable relief and improvement in symptoms.


Q: How long does the effect of one application of Leviogel typically last?

A: Studies related to the active ingredient indicate that the reduction in pain and inflammation is observed only as long as the medication is being used as directed. Official information suggests that improvements in pain relief have been noted to last up to eight hours following a single application in some studies.


Q: Why do some people refer to Leviogel as a 'fast-acting' gel?

A: The formulation uses a specialized gel base that is designed to efficiently allow the active ingredient to penetrate the skin. Because the medication works directly at the site of inflammation and pain, this allows for a more focused application compared to oral medicines.


Q: Do you need a prescription from a doctor to get Leviogel?

A: The prescription status of diclofenac topical gel often depends on its concentration and the region where it is sold. Official regulatory criteria in some regions allow for the gel to be available in both prescription (Rx) strengths and lower, over-the-counter (OTC) strengths (e.g., a 1% gel). The availability and required status are determined by the specific concentration and packaging authorized for sale in a given region.


Q: What happens if I miss a dose of Leviogel?

A: Official patient instructions describe management for missed doses. For example, if a missed dose is realized close to the next scheduled time, instructions generally suggest skipping the missed application. Instructions also emphasize that double doses should not be used.


Q: Why is the drug categorized as a Schedule X medication in some countries?

A: The classification or scheduling of diclofenac preparations varies widely among international governments and regulatory bodies. The designation (e.g., Schedule 1, 2, or 3) is typically based on factors such as the concentration of the active ingredient (e.g., 2% or less) and the maximum size of the package allowed for sale without a prescription for topical use.


Q: Has Leviogel been approved by major regulatory bodies like the FDA or EMA?

A: Topical diclofenac gels are approved and authorized by major regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This authorization ensures the product meets safety, efficacy, and quality standards for its specific, approved indications.


Q: Can Leviogel interact with herbal supplements like St. John's Wort?

A: Regulatory guidance often notes that complementary medicines, herbal remedies, and dietary supplements are generally not subject to the same rigorous testing as prescription drugs for potential interactions. Because of this information gap, patients are advised to inform their healthcare provider about all supplements, including herbal remedies like St. John's Wort, that they are currently using.


Q: Are there different strengths or formulations of Leviogel available?

A: The active ingredient, diclofenac, is officially available in multiple topical formats beyond this specific gel, which can include various concentrations (such as 1% or 3% gels), solutions, and patches. These different dosage forms are designed to achieve targeted delivery for specific indications.


Q: What are the main risks if Leviogel is accidentally swallowed?

A: Accidental ingestion of the topical gel is not a likely risk under normal use conditions. Regulatory safety information advises that if a large quantity is swallowed, a Poison Control center should be contacted immediately. This information emphasizes avoiding actions like inducing vomiting without specific medical instruction.


Q: Is the absorption rate of Leviogel affected by hot or cold application?

A: Leviogel is formulated to penetrate the skin and deliver the active ingredient directly to the site of pain and inflammation. The mechanism is independent of external temperature manipulation, meaning it works differently than using a standard cooling compress or a heating pad, which rely on stimulating skin nerves for temporary relief.


Q: Is Leviogel associated with any mental or mood side effects?

A: While mental or mood side effects are not listed as common reactions for the topical gel, rare effects have been reported with the NSAID drug class generally. These documented symptoms can include depression, anxiety, irritability, and nightmares.


Q: Are there any known interactions between Leviogel and alcohol consumption?

A: Regulatory information notes that co-administration of alcohol with diclofenac may be associated with an increased risk of certain systemic adverse effects. Specifically, this combination is associated with an increased risk of gastrointestinal (GI) bleeding and stomach ulcers, which is a known concern for the entire NSAID class of medicines.


Q: What if I experience a very rare side effect mentioned in the documentation?

A: If a very rare or serious adverse event is experienced, such as signs of a serious reaction or internal injury (like yellowing of the skin/eyes indicating liver issues or sudden weakness indicating a possible stroke), guidance on rare side effects advises that signs of a serious reaction may require seeking urgent medical help. It is important to know the signs of rare but serious effects documented on the label.

How should Leviogel be stored and disposed of?

How to Store and Dispose of Leviogel

Official regulatory guidelines mandate specific conditions to ensure the quality and safety of Leviogel (diclofenac sodium topical gel).

Storage Requirements

The gel must be stored at Controlled Room Temperature, defined as 20°C to 25°C (68°F to 77°F), with permitted temperature excursions up to 30°C. It is strictly required to Keep from freezing and to Protect from moisture. The product should be stored in a tight container and kept out of the reach of children.

Product Stability and Disposal

In-use stability after the first opening of the tube is officially documented as 6 months in some regions. Any unused or expired product, including the tube, must be disposed of in accordance with local requirements to prevent environmental contamination, particularly avoiding release into aquatic systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Leviogel found in:

A-Z Index: